egoropal
egis pharmaceuticals plc - paliperidonas - pailginto atpalaidavimo injekcinė suspensija užpildytame švirkšte - 100 mg - paliperidone
egoropal
egis pharmaceuticals plc - paliperidonas - pailginto atpalaidavimo injekcinė suspensija užpildytame švirkšte - 150 mg - paliperidone
asbima
zentiva k.s. - amlodipinas/valsartanas - plėvele dengtos tabletės - 5 mg/160 mg; 10 mg/160 mg - valsartan and amlodipine
brinzolamide elvim
sia elvim - brinzolamidas - akių lašai (suspensija) - 10 mg/ml - brinzolamide
tenofovir disoproxil sandoz
sandoz d.d. - tenofoviro dizoproksilis - plėvele dengtos tabletės - 245 mg - tenofovir disoproxil
valaciclovir elvim
sia elvim - valacikloviras - plėvele dengtos tabletės - 500 mg - valaciclovir
dalvocans
zentiva k.s. - kaspofunginas - milteliai infuzinio tirpalo koncentratui - 50 mg; 70 mg - caspofungin
fluconazole elvim
sia elvim - flukonazolas - kietosios kapsulės - 150 mg - fluconazole
tolvaptan accord
accord healthcare s.l.u. - tolvaptan - netinkamas adh sindromas - diuretikai, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrelio besilatas - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmento pakilimu ūmus miokardo infarktas, kartu su asr medikamentais gydytų pacientų, atitinkančių trombolizinė terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. daugiau informacijos, skaitykite skyrių 5.